Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main aim of this study is to compare the HAE attacks (both total and those requiring on-demand treatment) in the 12 months before and up to 24 months after initiation of treatment with lanadelumab.
This study is conducted in the United Kingdom where participants were treated or about to be treated with landelumab according to their routine practice at hospitals. Data will be directly collected from participants via study diaries, questionnaires, their medical records, and study doctors treating them. Participants will be contacted every 3 months during study participation (via phone).
Enrollment
Sex
Volunteers
Inclusion and exclusion criteria
Inclusion:
Exclusion:
• Exposure to lanadelumab administered as an investigation product in a clinical trial setting at any point in time
50 participants in 3 patient groups
Loading...
Central trial contact
Takeda Contact
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal